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Abstract. Vascular endothelial growth inhibitor (VEGI), also
known as tumour necrosis factor superfamily member 15
(TNFSF15) and TNF ligand related molecule 1 (TL1), is a
recently identified anti-angiogenic cytokine that belongs to
the TNF superfamily. Three isoforms of VEGI, VEGI 174,
192, and 251 have been documented, all sharing 151 common
C-terminal amino acids but differing in their N-terminal
regions. The investigations into the biological functions of
VEGI have pointed to a potential cancer inhibitory role for the
cytokine. The inhibitory effects of VEGI on cancer are
manifested in three main areas, the direct effect on cancer
cells, the anti-angiogenic effects on endothelial cells, and
stimulation of maturation of dendric cells. The clinical aspect
of VEGI in cancer is also being explored in recent years. The
present article overviews the recent progress on this molecule
and discusses the value of VEGI as a potential therapeutic
target in cancer therapy. 
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1. Introduction
Vascular endothelial growth inhibitor (VEGI) was first reported
in 1999 from human umbilical vein endothelial cells (1,2)
and was found to be identical to another gene known as
tumour necrosis factor superfamily member 15 (TNFSF15)
and TNF ligand related molecule 1 (TL1). The prime function
of VEGI was thought to be anti-angiogenic (1,2). Originally, it
was reported to be expressed exclusively in endothelial cells,
but more recently VEGI 251 was found to be highly
expressed in dendritic cells (DCs) after in vitro activation and
in inflammatory bowel disease (IBD), particularly Crohn's
disease (CD), rheumatoid arthritis, as well as renal inflammation
(3-6). It was believed to be one of the evolutionarily earliest
members of the TNF superfamily (7). There is evidence
showing that VEGI is involved in atherogenesis. Thus, VEGI
is a multipotential cytokine and plays a role in inflammation,
septic shock, fever, and growth modulation through the
functions of inducing apoptosis, regulating immunity, and
anti-angiogenesis. 
Moreover, other studies demonstrated an intricate
relationship between VEGI and carcinoma in vitro and in vivo
(8-11). It is a potent inhibitor of endothelial cell proliferation,
angiogenesis, and tumour growth (12). The present review
will briefly discuss the VEGI family and focus on the impact
of VEGI in cancer.
2. VEGI and the TNF superfamily
Three decades ago, lymphotoxin (LT) and tumour necrosis
factor-· (TNF) were identified as products of lymphocytes
and macrophages that cause lysis of certain types of cells,
especially tumour cells (13,14). The two molecules are
members of a gene superfamily (15,16). There are at least 19
members so far identified within this family (Table I), which is
generally referred to as tumour necrosis factor superfamily
(TNFSF). These proteins generally have an intracellular
N-terminal domain, a short transmembrane segment, an
extracellular stalk, and a globular TNF-like extracellular
domain of about 150 residues. These cytokines are either
type II transmembrane proteins (N-terminal inside the cell
and C-terminal outside the cell) or soluble proteins (17).
TNFSF and TNFSF receptor (TNFSFR) have a diverse array
of biological functions, including the growth regulation of
normal cells by inducing apoptosis or enhancing cell survival
and proliferation. In addition, TNF family members are
involved in regulating the immunity, inflammation, bone
metabolism, and organogenesis. As a late identified member
of the TNF family, VEGI (TNFSF15) shares certain homology
in amino acid sequence with other members of the same
family, and some of its functions are similar to other members,
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such as inducing apoptosis of epithelia cells. However, most
recent studies indicated potential implications of this molecule
in cancer and tumour related angiogenesis. 
3. Structure of VEGI and VEGI isoforms
In 1997, Tan et al identified a novel TNF-like molecule by
searching a cDNA database and named it TL1 (later known
as VEGI, TNFSF15 or TL1A) (1). These molecules are
abundant in arterial endothelial cells. Hydrophobicity analysis
of the protein revealed a 13 amino acid hydrophobic region
that follows the amino-terminal segment of 12 residues. VEGI
protein has a carboxyl terminus on the exterior cell surface
(residues 26-174), a single transmembrane domain, and a short
cytoplasmic tail. These features are consistent with characteristics
of type II transmembrane proteins.
VEGI protein has 20-30% sequence identity to other TNF
family members, except TNF-ß (2). The full gene of VEGI is
~17 kb, which consists of four exons and three introns and
mapped to human chromosome 9q32. To date, three splicing
variants of VEGI have been reported. The initially reported
VEGI protein is composed of 174 amino acids, of which the
1-25 AA residues at the N-terminus are the predicted intra-
cellular and transmembrane domain and the 26-174 residues
at the C-terminus form an extracellular domain. The intra-
cellular domain is released after a cleavage (8).
Two other isoforms, VEGI 251 and 192, were discovered
subsequently (10,18,19). VEGI 251 is encoded by exons I, II,
III b and IV, and VEGI 174 by exons IV and IV b. All three
isoforms share a common region of 453 bp that encodes a
domain of 24-174 amino acids at the C-terminus of VEGI 174.
However, the three isoforms differ in their N-terminal regions
due to alternative exons (Fig. 1) (18). In the three isoforms,
the longest and most abundant form of VEGI protein contains
251 amino acids and is also known as TL1A (20). Similar to
most tumour necrosis factor family members, VEGI 251 is a
type II membrane-bound protein with a hydrophobic trans-
membrane region near the N-terminus and an extracellular
carboxyl domain (containing 180 amino acid residues 72-251).
Its extracellular domain is cleaved off from the cell membrane
by unidentified protease(s) and exists in soluble form (7). The
cleavage at different sites generates other soluble forms of
VEGI 251 which have different functions, such as VEGI 72-
251, 101-251, and 106-251. In 2007, Jin et al crystallized
recombinant human VEGI 251, which belongs to the tetra-
gonal space group P41212. It has self-rotation functions with
three molecules in the asymmetry unit. The three VEGI 251
monomers in the asymmetric unit form a homotrimer that
resembles the trimer structure of other TNF ligand family
members (7,20). It is now known that only the solubilised
extracellular domain of the three isoforms of VEGI is
responsible for its biological activity (8,10,18,19,21). For
example, full-length VEGI 174 was found to have no effect
on tumour growth when over-expressed in cancer cells,
whereas a secretable fusion protein (sVEGI) comprising a
secretion signal peptide and the putative extracellular domain
of VEGI 174 inhibited tumour growth when over-expressed
in cancer cells (9,22,23).
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Table I. Members of TNF superfamily.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
TNF family ligands Human chromosome Full name Other names Reference
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
TNF-· 6p21.3 Tumor Necrosis factor-· (16,35,36)
TNF-ß 6p21.3 Tumor Necrosis factor-ß Lymphotoxin-a, LTA (15,37)
LTB 6p21.3 Lymphotoxin-ß TNFC (38)
CD27L 19p13 CD27 antigen ligand TNFSF7 (39)
CD30L, 1P36 CD30  antigen ligand TNFSF8, Ki-1 (40,41)
CD40L Xq26 CD40 antigen ligand CD154, TNFSF5,GP39 (42)
FasL 1q23 Fas ligand TNFSF6, CD95L, CD178 (43,44)
4-1BBL 19p13.3 TNFSF9 (45)
OX40L (TNFSF4) 1q25 OX40 antigen ligand GP34, TNFSF4, CD134L (46)
TRAIL 3q26 TNF-related apoptosis-inducing APO2L, TNFSF10 (47)
ligand
VEGI(TNFSF15) 9q32 Vascular endothelial growth inhibtor TL1, TNFSF15 (1)
ODF 13q14 Osteoclast differentiation factor OPGL, RANKL, TRANCE, TNFSF11 (48)
TNFSF13 (APRIL) TNF- and apol-related leukocyte TALL2, TNFSF13 (49)
expressed ligand 2
TNFSF12 17p13.3 TWEAK, TWEPRIL,INCLUDED (50,51)
BAFF 13q32-q34 B cell activating factor TNFSF13B, BLYS, TALL1, THANK (52)
LITAF 16p13.3-p12 LPS-induced TNF-· factor SIMPLE (53)
TNFSF18 1q23 AITRL, GITRL (54,55)
TNFSF14 19p13.3 HVEML (56,57)
C1QTNF5 11q23.3 C1q and tumor necrosis CTRP5 (58)
factor-related protein 5
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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4. Expression and cell/tissue distribution of VEGI
VEGI was originally thought to be exclusively expressed in
endothelial cells (24). VEGI 251 and 192 were also detected
in the same cell types including HCAE, HUVE, and HMVE
cells, but are not seen in HCASM and ABAE. It should also
be noted that more than one isoform is expressed in the same
cell type, in which VEGI 251 is the most abundant. It is
interesting to note that VEGI is highly expressed in some
vascularised tissues, such as the kidney but not in other
vascularised tissues, such as the heart. This indicates that only
a subset of endothelial cells in the tissues expresses VEGI
(2). It was found that VEGI is highly expressed in dendritic
cells (DCs) after in vitro activation and also up-regulated in
Crohn's disease, rheumatoid arthritis, and mouse models of
inflammatory bowel disease (3,25,26). Furthermore, VEGI
expression was also found in activated lymphocytes, plasma
cells, and monocytes (24,25,27). 
On the other hand, the tissue distribution of VEGI and its
isoforms were also examined. Using Northern blotting, the
VEGI transcript was found to be expressed in placenta, lung,
kidney, skeletal muscle, pancreas, spleen, prostate, small
intestine, and colon. VEGI signal was only rarely detected in
heart, brain, liver, thymus, testis, ovary, and peripheral blood
lymphocytes (2). VEGI isoforms also have different tissue
expression patterns. A 7.5 kb VEGI 251 transcript was detected
in placenta, kidney, lung, and liver, whereas the 2 kb VEGI 174
transcript was observed in liver, kidney, skeletal muscle, and
heart. VEGI 251 and 174 were both expressed in prostate,
salivary gland, and placenta. However, VEGI 251 is more
abundant than VEGI 174 in fetal kidney and lung, whereas
VEGI 174 is more abundant in heart, skeletal muscle, pancreas,
adrenal gland, and liver (18). VEGI 192 RNA is generally low
in tissues and little information is available on this isoform. 
5. Regulation of VEGI expression 
It was reported that TNF-· upregulates the expression of
VEGI transcripts in endothelial cells (18). On the other hand,
IFN-Á showed a suppressive effect on the expression of both
basal levels of VEGI, as well as TNF-stimulated VEGI
expression. 
VEGI utilizes death receptor 3 (DR3, also known as
TNFRSF25) for its biological functions. VEGI activation
results in activation of nuclear factor-κB (NF-κB), a central
transcription factor that controls expression of numerous genes
in the immune system. Recombinant soluble VEGI induces
NF-κB activation in DR3-expressing cells and increases ectopic
expression of VEGI in human endothelial cells (18). This
suggests VEGI regulates its own expression in an autocrine
manner. In a mouse model, it was found that a full-length
mouse VEGI gene is transcribed from a major transcription
initiation site. Critical control of VEGI expression resides in a
segment within the promoter that carries NF-κB and specificity
protein-1 (SP1) binding sites, and binding of NF-κB to this site
is important for basal and TNF-· induced VEGI expression
(22). 
6. VEGI and angiogenesis
Angiogenesis is essential for many physiological (as seen in
uterus and in wound healing) and pathological (such as cancer,
rheumatoid arthritis and diabetes) processes (28,29). The
process of angiogenesis involves cell proliferation, migration,
tubule formation of endothelial cells, remodelling of the extra-
cellular matrix, and invasion to surrounding tissue (30), and
is tightly regulated by a balance of pro- and anti-angiogenic
molecules (9,30). A number of endogenous angiogenesis
inhibitors, such as angiostatin, endostatin, restin, canstatin, and
tumstatin were reported and have been shown to suppress the
growth of primary and metastatic tumours without affecting
the normal vasculature (31). 
VEGI induces apoptosis in endothelial cells via an autocrine
pathway (2,18,32). Its mRNA was also found in many normal
and tumour tissues, and tumour cell lines, suggesting a physio-
logical and pathological role for this unique molecule in the
regulation of new vasculature. Over-expression of VEGI was
shown to inhibit tumour neovascularisation and progression
in cellular and animal models (8,32). 
Using recombinant VEGI protein consisting of the putative
extracellular domain of VEGI, it was found that the protein
inhibited the growth of capillary-like structures regardless of
the cause of the angiogenic process in vitro and markedly
inhibits the growth of breast cancer and colon cancer xenograft
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Figure 1. The amino acid structure of the three isoforms of VEGI. VEGI 251, 192, and 174 share a common region of 151 amino acids at the C-terminus (in black
boxes). VEGI 251 and 192 share another identical 15 amino acids next to the common region (in gray boxes). However, the three isoforms differ in their N-terminal
regions (in blank boxes). The molecular weight of VEGI 251, 192, and 174 is 28,087, 21,857, and 20,131 Da, respectively. In VEGI 251, the extracellular carboxyl
domain contains 72-251AA. In VEGI 174, the extracellular carboxyl domain contains 26-174AA. The exact extracellular carboxyl domain of VEGI 192 was not
reported previously. In VEGI 251, the cleavage site was in 71 and 72 amino acids. Another cleavage site (XVVR) which was verified in VEGI 174 and 251 also
exists in VEGI 192. ΔCleavage site.
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tumours (2,8). The antitumour effect of VEGI is likely to result
from the ability of VEGI to suppress neovascularisation
because recombinant VEGI has no inhibitory activity on the
growth of cancer cells in vitro. Furthermore, over-expression of
VEGI 251 induced apoptosis in endothelial cells (18) and
inhibited the growth of xenograft tumours and corresponding
microvessel density (18). However, over-expression of full-
length VEGI 174 by cancer cells has little effect on the growth
of the xenograft tumours. Further investigation has shown that
the density of endothelial cells exhibited an 88% decrease
within 1 week of treatment with recombinant human VEGI
192 and a further decrease within 3 weeks (10). Interestingly,
the number of the smooth muscle cells remained relatively
unchanged. However, it was unclear whether the residual
vascular structures would supply enough blood circulation in
the tumours. Nonetheless, additional evidence indicates that
the antitumour activity of sVEGI is not due to a direct effect
on tumour cells but rather to an interference with the
development of tumour-associated vasculature (22,28). 
A few mechanisms underlying the inhibitory effect of
VEGI on endothelial cells were revealed. First, VEGI prevents
G0/G1 cells from re-entering the cell cycle in response to
growth stimuli. Second, there are two members of the TNF
receptor superfamily which VEGI interacts with, namely
death receptor 3 (DR3) and decoy receptor 3 (DcR3). DR3 is
the functional receptor of VEGI 251. It contains a death
domain in its cytoplasmic tail and induces apoptosis in death
receptor-3-expressing cell lines, such as in human umbilical
vein endothelial cells (HUVECs). On the contrary, previous
studies indicated that DcR3 is over-expressed in malignant
tumours arising from oesophagus, stomach, glioma, lung,
colon, and rectum (20,22,25-27). DcR3 enhances angio-
genesis by blocking the autocrine angiostatic function of
VEGI in human umbilical vein endothelial (27). Meanwhile,
anti-VEGI and -DR3 antibodies lead to increases of both cell
proliferation and motility, and an induction of the formation
of tube network (28). The angiogenic effect of VEGI antibody
and DR3 antibody is similar to that induced by DcR3.
Furthermore, VEGI induces apoptosis in actively proliferating
cells, via activation of the stress protein kinases, SAPK/JNK
and p38 MAPK (SAPK, stress-activated protein kinase, JNK,
c-Jun N-terminal protein kinase, p38 MAPK, p38 mitogen-
activated protein kinase), and the caspases, mainly caspase-3-
like protease. Additionally, VEGI-induced apoptosis is
attenuated by the caspase inhibitor.
In contrast, no obvious inhibitory effect on proliferation of
the blood vessels of chorioallantoic membrane was seen after
treatment with VEGI 72-251 in another study (19). The authors
suggested that although the 151 residues at the C-terminal of
VEGI 72-251 is identical with that of VEGI 24-174, the
assay of biological activity found that VEGI 72-251 did not
possess the biological activities of VEGI 24-174, such as
inhibiting the growth of endothelial cells. The results indicated
that soluble VEGI 72-251 is not able to bind with endothelial
cells, which is due to a change of protein structure. Another
investigation reported that truncated VEGI 251 proteins, which
correspond to amino acids 101-251 and 106-251 of VEGI 251,
both have an antiangiogenic effect (24). 
The C-terminus 151 amino acids from all known forms of
VEGI are the same and this part of the protein, when expressed
alone, induced apoptosis of endothelial cells within 36 h. Over-
expression of the full-length VEGI did not give rise to a VEGI
peptide in cell conditioned media and did not show anti-
angiogenic activity in vivo. This suggests the soluble domain
of VEGI is critical for this negative regulator of angiogenesis
produced predominantly by endothelial cells, but not when it
is associated with the amino-terminal cytoplasmic and trans-
membrane domains of VEGI (residues 1-23). Endothelial cell-
secreted VEGI functions as an autocrine inhibitor of angio-
genesis and a naturally existing modulator of vascular homeo-
stasis. Thus, this novel gene is not only vital for future study of
vascular biology but also is a potential target in the development
of angiogenesis-based cancer therapy.
7. Implication of VEGI in solid tumours
The expression and effect of VEGI were investigated in a wide
variety of human cancer cell lines, including breast, prostate,
bladder, colorectal and liver, and also expressed in human
epithelial cells (9). Moreover, recent studies revealed a
profound implication of VEGI in clinical cancer. 
VEGI is able to inhibit the growth of various human tumour
cell lines including human histiocytic lymphoma (U-937),
human breast carcinoma (MCF-7), human epithelial carcinoma
(HeLa) and human myeloid lymphoma ML-1a (11). VEGI
was also shown to inhibit tumour growth in vivo. VEGI also
suppresses the growth of colon carcinoma cells (murine colon
cancer cells, MC-38) both in vitro and in vivo (2,8,22).
Systemic administration of VEGI 192 remarkably inhibited
tumour growth and increased survival time of the treated
animals in a Lewis lung cancer (LLC) murine tumour model.
As much as 50% inhibition of the tumour growth rate was
achieved with treatment from which no obvious liver and
kidney toxicity was found (10). In 2006, Parr et al reported
that patients with breast tumours expressing reduced levels of
VEGI had a higher local recurrence, shorter survival time and
an overall poorer prognosis than those patients expressing high
levels of VEGI. In addition, VEGI levels tended to be lower in
lobular tumours compared to tumours of ductal origin.
However, no significant correlations were observed between
VEGI expression and tumour grade, TNM classification, or
nodal involvement (9). It is plausible that the pro-apoptotic
effect of soluble VEGI in endothelial cells is critical for its
anti-tumour activity (10,19-22,28,32,33). However, it is unclear
whether other mechanisms, such as activation of tumour-
specific or non-specific B or T lymphocytes or induction of
cytokines (18), also operate in the soluble VEGI-mediated
tumour suppression. 
8. Other functions of VEGI involved in carcinoma
VEGI is a T cell costimulator. It directly stimulates DC
maturation, and induces nuclear factor-κB activation and
apoptosis in death receptor-3-expressing cell lines. However,
it is unclear whether these mechanisms are involved in the
VEGI-mediated tumour suppression.
The structure of VEGI itself is of interest when considering
its functions. While VEGI 24-174 is anti-angiogenic, VEGI 72-
251 serves as an anti-cancer factor through its activation of
T lymphocytes (19,20). VEGI 72-251, not VEGI 24-174, binds
ZHANG et al:  VEGI IN CANCER6
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T cell receptors. The functional receptor for VEGI 251 is DR3
(6), which is predominantly expressed on activated lympho-
cytes. Ligand-receptor binding creates co-stimulatory signals
for T cells, increases IL-2 responsiveness and secretion of
IFN-Á and GM-CSF, both in vitro and in vivo. There are
suggestions that the anti-cancer activities of VEGI 72-251
mainly depend on the stimulation of T cells but not on anti-
angiogenesis (19,20,24). Moreover, VEGI 251 binds to DR3
and activates NF-κB, caspase, induces c-IAP2 production and
regulates DR3 mediated apoptosis in the tumour cell line TF-1
(20,24,34). However, this interaction fails to induce significant
caspase activation or apoptosis in T cells. These results
suggest that VEGI 251 and DR3 are involved in multiple
diseases where immunity plays a major role. VEGI 251
mediates cancer rejection through tumour-specific or non-
specific B or T lymphocytes or induction of cytokines.
However, these functions are inhibited in the presence of a
decoy receptor (DcR3, also known as TR6, or TNFRSF21),
which competes for the binding of VEGI 251 (20,24,34).
Upon binding to DR3, VEGI 251 directly stimulates DC
maturation, which is an essential component of host immunity
against cancer development (33). Collectively, it suggests that
VEGI 251 plays a central role in the interaction between the
endothelium and the immune system to modulate angio-
genesis and inflammation toward the suppression of tumour
development and progression.
9. Perspective
Further investigation of VEGI and the signal pathways will
expand the understanding of its role in cancer and tumour
related angiogenesis. For example, the exact membrane
receptor responsible for VEGI induced endothelial cell
apoptosis is yet to be clarified. Second, underlying mechanisms,
such as activation of tumour- or non-specific B or T lympho-
cytes or induction of cytokines and soluble VEGI-mediated
tumour rejection are yet to be established (2). Third, the up-
regulation of VEGI transcripts by TNF-· indicates that VEGI-
mediated activity is potentially a target of TNF-· action.
Fourth, the clinical impact of circulating VEGI in cancer should
be studied in detail. It was reported that VEGI is not only
expressed in HUVECs but also secreted to the culture medium
(28). In certain inflammatory diseases, VEGI also has a
remarkable increase in peripheral blood. Little is known
about the serum level of VEGI in cancer. Synthetic chimeric
protein VEGI-CTT was demonstrated to be an effective
inhibitor of lymphoma tumour growth in vivo, and it has a
more potent antitumour activity than VEGI, CTT, or the
combination of both (28). Further investigation will highlight
the regulation of VEGI functions by other anti-angiogenesis
or -cancer factors. 
VEGI serves as a potential target in the development of
angiogenesis-based cancer therapy. In contrast to the function
of DR3, a soluble DcR3 is generated to interfere with the auto-
crine function of VEGI (28). Increasing expression of DcR3
was indicated in various solid tumours, which protects
vascular endothelial cells from induced apoptosis by VEGI
and contributes to tumour related angiogenesis. Targeting at
DcR3 has provided a potential approach to block tumour
associated angiogenesis. 
In summary, the aberrance of VEGI expression and function
was implicated in carcinoma and related angiogenesis. Future
study will elucidate mechanisms of VEGI regulation and its
role in angiogenesis under both physiological and pathological
conditions. It will also provide novel therapeutic approaches
for targeting carcinoma and angiogenesis.
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